Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to four new employees hired in September 2024. The awards include non-qualified stock options to purchase a total of 33,600 shares of Adicet's common stock at an exercise price of $1.44 per share.
The vesting schedule for these options is as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan. The compensation committee authorized the awards as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), un'azienda di biotecnologia in fase clinica focalizzata sulle terapie cellulari gamma delta T allogeniche, ha concesso premi di incitamento a quattro nuovi dipendenti assunti a settembre 2024. I premi includono opzioni su azioni non qualificate per acquistare un totale di 33.600 azioni delle azioni ordinarie di Adicet a un prezzo di esercizio di $1,44 per azione.
Il piano di maturazione per queste opzioni è il seguente: 25% delle azioni maturerà nel primo anniversario della data di assunzione di ciascun destinatario, mentre il restante 75% maturerà in 36 rate mensili successivamente. La maturazione completa avverrà al quarto anniversario della data di assunzione del destinatario, soggetto a un impiego continuato.
Questi premi sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti di Adicet, nell'ambito del 2022 Inducement Plan dell'azienda. Il comitato per la compensazione ha autorizzato i premi come un incentivo materiale per l'occupazione, in conformità con il Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), una empresa de biotecnología en etapa clínica centrada en terapias celulares gamma delta T alogénicas, ha otorgado premios de inducción a cuatro nuevos empleados contratados en septiembre de 2024. Los premios incluyen opciones sobre acciones no calificadas para comprar un total de 33,600 acciones de las acciones ordinarias de Adicet a un precio de ejercicio de $1.44 por acción.
El cronograma de adquisición para estas opciones es el siguiente: 25% de las acciones se adquirirán en el primer aniversario de la fecha de inicio de cada destinatario, y el 75% restante se adquirirá en 36 cuotas mensuales a partir de entonces. La adquisición completa ocurrirá en el cuarto aniversario de la fecha de inicio del destinatario, sujeto a un empleo continuo.
Estos premios se otorgaron fuera de los planes de incentivos de equidad aprobados por los accionistas de Adicet, bajo el 2022 Inducement Plan de la empresa. El comité de compensación autorizó los premios como un incentivo material para el empleo, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET), 동종 유래 감마 델타 T 세포 치료제를 전문으로 하는 임상 단계 생명공학 회사는 2024년 9월에 채용된 4명의 신규 직원에게 유인 보상을 수여했습니다. 이 보상에는 비적격 주식 옵션이 포함되어 있으며, Adicet의 보통주 33,600주를 주당 $1.44의 행사 가격으로 구매할 수 있습니다.
이 옵션의 배당 일정은 다음과 같습니다: 25%의 주식은 각 수령자의 시작일 1주년 기념일에 배분되며, 나머지 75%는 이후 36개월에 걸쳐 매달 배분됩니다. 전체 배당은 수령자의 시작일 4주년 기념일에 이루어지며, 지속적인 고용을 조건으로 합니다.
이 보상은 Adicet의 주주 승인 자산 인센티브 계획 외부에서 2022 유인 계획의 일환으로 수여되었습니다. 보상 위원회는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용에 대한 실질적인 유인으로서 보상을 승인했습니다.
Adicet Bio (Nasdaq: ACET), une entreprise de biotechnologie en phase clinique axée sur les thérapies cellulaires allogéniques gamma delta T, a octroyé des prix d'incitation à quatre nouveaux employés recrutés en septembre 2024. Les prix incluent des options d'achat d'actions non qualifiées permettant l'achat d'un total de 33 600 actions des actions ordinaires d'Adicet à un prix d'exercice de 1,44 $ par action.
Le calendrier d'acquisition pour ces options est le suivant : 25% des actions seront acquises à la date anniversaire d'un an du début de chaque destinataire, tandis que les 75% restantes seront acquises par tranches mensuelles sur 36 mois par la suite. L'acquisition complète interviendra au quatrième anniversaire de la date de début du destinataire, sous réserve d'un emploi continu.
Ces prix ont été octroyés en dehors des plans d'incitation par actions approuvés par les actionnaires d'Adicet, dans le cadre du 2022 Inducement Plan de l'entreprise. Le comité de rémunération a autorisé les prix en tant qu'incitation matérielle à l'emploi, conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf allogene Gamma-Delta-T-Zelltherapien konzentriert, hat Incentive-Auszeichnungen für vier neue Mitarbeiter, die im September 2024 eingestellt wurden, vergeben. Die Auszeichnungen umfassen nicht qualifizierte Aktienoptionen zum Kauf von insgesamt 33.600 Aktien des Stammkapitals von Adicet zu einem Ausübungspreis von $1,44 pro Aktie.
Der Vesting-Zeitrahmen für diese Optionen ist wie folgt: 25% der Aktien werden am einjährigen Jubiläum des Beginns eines jeden Empfängers fällig, während die verbleibenden 75% in 36 monatlichen Raten danach fällig werden. Die vollständige Vesting erfolgt am vierten Jahrestag des Beginns des Empfängers, vorbehaltlich einer anhaltenden Anstellung.
Diese Auszeichnungen wurden außerhalb der von Adicets Aktionären genehmigten Eigenkapital-Anreizpläne im Rahmen des 2022 Inducement Plan des Unternehmens gewährt. Der Vergütungsausschuss genehmigte die Auszeichnungen als wesentliche Anreiz zur Beschäftigung, gemäß der Nasdaq Listing Regel 5635(c)(4).
- Adicet Bio is attracting new talent with stock option incentives
- The company has a structured vesting schedule to encourage employee retention
- The stock options were granted at a relatively low price of $1.44 per share, potentially indicating a depressed stock value
Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 33,600 shares of Adicet’s common stock with an exercise price of
All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930984918/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
How many new employees received inducement awards from Adicet Bio (ACET) in September 2024?
What is the exercise price for the stock options granted by Adicet Bio (ACET) on September 30, 2024?
How many shares of Adicet Bio (ACET) common stock were granted as non-qualified stock options?
What is the vesting schedule for the inducement awards granted by Adicet Bio (ACET)?
